肝移植前免疫检查点抑制剂治疗——病例与文献综述 - Suppr

Suppr

超能文献

Immune Checkpoint Inhibitor Therapy Before Liver Transplantation-Case and Literature Review.

作者信息

Aby Elizabeth S, Lake John R

机构信息

Division of Gastroenterology, Hepatology, and Nutrition, University of Minnesota, Minneapolis, MN.

出版信息

Transplant Direct. 2022 Mar 10;8(4):e1304. doi: 10.1097/TXD.0000000000001304. eCollection 2022 Apr.

DOI:10.1097/TXD.0000000000001304

PMID:35310602

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8923608/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/16f1/8923608/2db32fc45fbf/txd-8-e1304-g001.jpg

相似文献

Immune Checkpoint Inhibitor Therapy Before Liver Transplantation-Case and Literature Review.肝移植前免疫检查点抑制剂治疗——病例与文献综述

Transplant Direct. 2022 Mar 10;8(4):e1304. doi: 10.1097/TXD.0000000000001304. eCollection 2022 Apr.

Immune Checkpoint Inhibitors in Patients with Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Case Report and Literature Review.免疫检查点抑制剂在肝移植后复发性肝细胞癌患者中的应用：病例报告及文献复习。

Curr Cancer Drug Targets. 2020;20(9):720-727. doi: 10.2174/1568009620666200520084415.

Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy-Review of the Literature and Future Outlook.与纳武单抗、伊匹单抗和帕博利珠单抗治疗相关的神经免疫相关不良事件——文献综述与未来展望

J Clin Med. 2019 Oct 24;8(11):1777. doi: 10.3390/jcm8111777.

Immune checkpoint inhibitors in neuroendocrine tumors: A single institution experience with review of literature.神经内分泌肿瘤中的免疫检查点抑制剂：单机构经验及文献综述

Oncotarget. 2017 Dec 28;9(10):8801-8809. doi: 10.18632/oncotarget.23753. eCollection 2018 Feb 6.

Pretransplant use of toripalimab for hepatocellular carcinoma resulting in fatal acute hepatic necrosis in the immediate postoperative period.术前使用特瑞普利单抗治疗肝细胞癌，导致术后即刻发生致命性急性肝坏死。

Transpl Immunol. 2021 Jun;66:101386. doi: 10.1016/j.trim.2021.101386. Epub 2021 Mar 18.

Management Considerations for Immune Checkpoint Inhibitor-Induced Enterocolitis Based on Management of Inflammatory Bowel Disease.基于炎症性肠病治疗的免疫检查点抑制剂相关性肠炎的管理考虑

Inflamm Bowel Dis. 2020 Apr 11;26(5):662-668. doi: 10.1093/ibd/izz212.

The Role of Immune Checkpoint Molecules for Relapse After Allogeneic Hematopoietic Cell Transplantation.免疫检查点分子在异基因造血细胞移植后复发中的作用。

Front Immunol. 2021 Mar 5;12:634435. doi: 10.3389/fimmu.2021.634435. eCollection 2021.

Association of Immune-Mediated Cerebellitis With Immune Checkpoint Inhibitor Therapy.免疫介导性小脑炎与免疫检查点抑制剂治疗的关联

Mayo Clin Proc Innov Qual Outcomes. 2018 Feb 1;2(1):74-77. doi: 10.1016/j.mayocpiqo.2017.12.001. eCollection 2018 Mar.

Immune Checkpoint Inhibitors in Organ Transplant Patients.器官移植患者中的免疫检查点抑制剂

J Immunother. 2017 Sep;40(7):277-281. doi: 10.1097/CJI.0000000000000180.

Evaluation of arthralgias in adult oncology patients receiving immune checkpoint inhibitors.

J Oncol Pharm Pract. 2019 Dec;25(8):1867-1872. doi: 10.1177/1078155218822707. Epub 2019 Jan 16.

引用本文的文献

Liver transplantation in a patient with metastatic hepatocellular carcinoma after downstaging with single-agent immunotherapy: the first case report.单药免疫治疗降期后转移性肝细胞癌患者的肝移植：首例病例报告

J Gastrointest Oncol. 2025 Jun 30;16(3):1321-1330. doi: 10.21037/jgo-24-764. Epub 2025 Jun 26.

Liver resection and transplantation in the era of checkpoint inhibitors.免疫检查点抑制剂时代的肝切除与肝移植

JHEP Rep. 2024 Aug 6;6(11):101181. doi: 10.1016/j.jhepr.2024.101181. eCollection 2024 Nov.

APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024.2024年亚太肝脏研究学会肝细胞癌全身治疗临床实践指南

Hepatol Int. 2024 Dec;18(6):1661-1683. doi: 10.1007/s12072-024-10732-z. Epub 2024 Nov 21.

Immune Checkpoint Inhibitors in the Pre-Transplant Hepatocellular Carcinoma Setting: A Glimpse Beyond the Liver.免疫检查点抑制剂在移植前肝细胞癌治疗中的应用：肝脏之外的探索。

Int J Mol Sci. 2024 Oct 30;25(21):11676. doi: 10.3390/ijms252111676.

Downstaging of advanced hepatocellular carcinoma followed by liver transplantation using immune checkpoint inhibitors: Where do we stand?使用免疫检查点抑制剂后进行肝移植的晚期肝细胞癌降期：我们目前的进展如何？

World J Gastrointest Pharmacol Ther. 2024 Sep 5;15(5):97570. doi: 10.4292/wjgpt.v15.i5.97570.

Liver Transplantation for Hepatocellular Carcinoma in the Era of Immune Checkpoint Inhibitors.免疫检查点抑制剂时代肝细胞癌的肝移植

Cancers (Basel). 2024 Jun 28;16(13):2374. doi: 10.3390/cancers16132374.

Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis.移植前免疫检查点抑制剂的使用对肝癌移植后结局的影响：一项系统评价和个体患者数据荟萃分析。

J Hepatol. 2025 Jan;82(1):107-119. doi: 10.1016/j.jhep.2024.06.042. Epub 2024 Jul 10.

Contemporary Systemic Therapy Approaches for Unresectable Hepatocellular Carcinoma.不可切除肝细胞癌的当代系统治疗方法

Adv Oncol. 2024 May;4(1):233-246. doi: 10.1016/j.yao.2024.02.001. Epub 2024 Feb 23.

Patients treated with immune checkpoint inhibitors for HCC should not be considered for liver transplant.接受免疫检查点抑制剂治疗的肝癌患者不应考虑进行肝移植。

Clin Liver Dis (Hoboken). 2024 May 8;23(1):e0108. doi: 10.1097/CLD.0000000000000108. eCollection 2024 Jan-Jun.

Transplant Oncology: An Emerging Discipline of Cancer Treatment.移植肿瘤学：癌症治疗的一门新兴学科。

Cancers (Basel). 2023 Nov 9;15(22):5337. doi: 10.3390/cancers15225337.

本文引用的文献

Neoadjuvant Programmed Cell Death 1 (PD-1) Inhibitor Treatment in Patients With Hepatocellular Carcinoma Before Liver Transplant: A Cohort Study and Literature Review.新辅助程序性细胞死亡 1（PD-1）抑制剂治疗肝癌患者肝移植前：队列研究和文献复习。

Front Immunol. 2021 Jul 19;12:653437. doi: 10.3389/fimmu.2021.653437. eCollection 2021.

Transpl Immunol. 2021 Jun;66:101386. doi: 10.1016/j.trim.2021.101386. Epub 2021 Mar 18.

PD-1 inhibitor as bridge therapy to liver transplantation?PD-1抑制剂作为肝移植的桥接治疗？

Am J Transplant. 2021 May;21(5):1979-1980. doi: 10.1111/ajt.16448. Epub 2021 Jan 2.

Immunotherapy as a Downstaging Therapy for Liver Transplantation.免疫疗法作为肝移植的降期治疗方法。

Hepatology. 2020 Oct;72(4):1488-1490. doi: 10.1002/hep.31234.

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial.帕博利珠单抗作为 KEYNOTE-240 中晚期肝细胞癌二线治疗的疗效：一项随机、双盲、III 期试验。

J Clin Oncol. 2020 Jan 20;38(3):193-202. doi: 10.1200/JCO.19.01307. Epub 2019 Dec 2.

Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient?尼伏单抗桥接肝移植治疗 HCC 后致死性肝坏死：免疫检查点抑制剂对移植前患者安全吗？

Am J Transplant. 2020 Mar;20(3):879-883. doi: 10.1111/ajt.15617. Epub 2019 Oct 28.

Immune checkpoint inhibitor therapy in solid organ transplant recipients: A patient-centered systematic review.实体器官移植受者的免疫检查点抑制剂治疗：一项以患者为中心的系统评价。

J Am Acad Dermatol. 2020 Jun;82(6):1490-1500. doi: 10.1016/j.jaad.2019.07.005. Epub 2019 Jul 11.

Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature.实体器官移植受者中癌症的检查点抑制剂治疗：机构经验和文献系统评价。

J Immunother Cancer. 2019 Apr 16;7(1):106. doi: 10.1186/s40425-019-0585-1.

Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience.对有肝移植史的转移性癌症患者进行PD-1抑制的初步评估：梅奥诊所的经验

J Gastrointest Oncol. 2018 Dec;9(6):1054-1062. doi: 10.21037/jgo.2018.07.05.

Liver Allograft Failure After Nivolumab Treatment-A Case Report With Systematic Literature Research.纳武单抗治疗后肝移植失败——一例报告及系统文献研究

Transplant Direct. 2018 Jul 20;4(8):e376. doi: 10.1097/TXD.0000000000000814. eCollection 2018 Aug.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验